KCNC2 and Prolonged QT interval: In addition to norfluoxetine blocking both Kv3.2 WT and V473A channels more effectively than fluoxetine, norfluoxetine is also a more potent selective serotonin reuptake inhibitor (SSRI) than fluoxetine (Eli-Lilly and Company, 2006; Wong et al., 1993) but has not been marketed by pharma in this role because its effects on a cardiac potassium channel are associated with long-QT syndrome (Magyar et al., 2004).